| New bispecific antibody that specifically binds to cluster of differentiation (CD)3 and ganglioside (GD2) comprising antigen-binding fragments that binds to CD3 and GD2 respectively and having variable domains used to treat e.g. brain tumor | |
| 2023-03-10 | |
| 专利权人 | BIOCAD STOCK CO (BOCD-C) |
| 申请日期 | 2023-03-10 |
| 专利号 | RU2023105631-A |
| 成果简介 | NOVELTY - Bispecific antibody that specifically binds to cluster of differentiation (CD)3 and ganglioside (GD2) and comprising (1) first antigen-binding fragment that specifically binds to CD3 and comprises light chain variable domain specifically binding to CD3 comprising complementarity determining region (CDR)s 1-3 of SEQ ID NOs: 1-3, SEQ ID NOs: 4-6 and a heavy chain variable domain of the first antigen-binding fragment that specifically binds to CD3 comprising: CDRs1-3 of SEQ ID NOs: 7-9, SEQ ID NOs: 10-12, and (2) a second antigen-binding fragment that specifically binds to GD2 and comprises: (a) a light chain variable domain comprising: (i) CDRs1-3 of SEQ ID NOs: 13-15 and (b) a heavy chain variable domain comprising: (i) CDRs 1-3 of SEQ ID NOs: 16-18, is new. USE - The bispecific antibody is useful in a composition for treating a disease or disorder mediated by GD2 including brain tumor, neuroblastoma, glioblastoma, medulloblastoma, retinoblastoma, astrocytoma, melanoma, B-cell lymphoma, small cell lung cancer, renal cell carcinoma, desmoplastic small round cell fibroma, osteosarcoma, Ewing's sarcoma, breast cancer, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, fibrosarcoma or soft tissue sarcoma (all claimed). No Biological data given. ADVANTAGE - None given. DETAILED DESCRIPTION - Bispecific antibody that specifically binds to cluster of differentiation (CD)3 and ganglioside (GD2) and comprising: (1) a first antigen-binding fragment that specifically binds to CD3 and comprises: (i) (a) a light chain variable domain of the first antigen-binding fragment that specifically binds to CD3 comprising: complementarity determining region (CDR)s 1-3 of SEQ ID NOs: 1-3, and (b) a heavy chain variable domain of the first antigen-binding fragment that specifically binds to CD3 comprising: CDRs1-3 of SEQ ID NOs: 7-9, or (ii) (a) a light chain variable domain of a first antigen-binding fragment that specifically binds to CD3, comprising: a CDRs 1-3 of SEQ ID NOs: 4-6, and (b) a heavy chain variable domain of the first antigen-binding fragment, which specifically binds to CD3, comprising: CDRs 1-3 of SEQ ID NOs: 10-12, and (2) a second antigen-binding fragment that specifically binds to GD2 and comprises: (a) a light chain variable domain comprising: (i) CDRs1-3 of SEQ ID NOs: 13-15 and (b) a heavy chain variable domain comprising: (i) CDRs 1-3 of SEQ ID NOs: 16-18, is new. INDEPENDENT CLAIMS are also included for: (1) isolated nucleic acid that encodes a bispecific antibody; (2) expression vector comprising the nucleic acid; (3) producing a host cell for producing a bispecific antibody, comprising transforming the cell with the vector; (4) host cell for producing an antibody or its antigen-binding fragment, containing the nucleic acid; (5) producing a bispecific antibody; and (6) treating a disease or disorder mediated by GD2, comprising administering a bispecific antibody and (a) administration of at least one other active compound, (b) radiation therapy, (c) hematopoietic stem cell transplantation and/or (d) surgical treatment and, if necessary, adjuvant therapy. |
| IPC 分类号 | A61K-039/395 |
| 国家 | 俄罗斯 |
| 专业领域 | 生物科学 |
| 语种 | 英语 |
| 成果类型 | 专利 |
| 文献类型 | 科技成果 |
| 条目标识符 | http://119.78.100.226:8889/handle/3KE4DYBR/22192 |
| 专题 | 中国科学院新疆生态与地理研究所 |
| 作者单位 | BIOCAD STOCK CO (BOCD-C) |
| 推荐引用方式 GB/T 7714 | AGEEV S A,CHERNYKH YU S,KONDINSKAYA D A,et al. New bispecific antibody that specifically binds to cluster of differentiation (CD)3 and ganglioside (GD2) comprising antigen-binding fragments that binds to CD3 and GD2 respectively and having variable domains used to treat e.g. brain tumor. RU2023105631-A[P]. 2023. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论